Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q1 2016 · 10-Q
Revenue$31.28M$31.28M−8.5% vs Q1 2015 Net Income-$23.20M-$23.20MN/M vs Q1 2015 EPS Diluted-$0.61-$0.61N/M vs Q1 2015 Operating Income-$23,594,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
Free Cash Flowderived-$21,542,000N/M Margins · derivedOperating margin-75.4%−60.2 pt vs Q1 2015
Net margin-74.2%−59.7 pt vs Q1 2015
ended Mar 31, 2016 · filed May 9, 2016 · 39 d after period end